Belatacept
As of the edition of 20 October 2026, Belatacept is a protein: marketed, first approved in 2011 (US); acts on CD80 and CD86; US protection ended in 2023.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Protein
- Brand name
- Nulojix
- First approved
- 15 June 2011 (US)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Bristol Myers Squibb
- Registered trials
- 63, 8 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Immune system; Hormones; Nutrition and metabolism; Infections
US protection
US protection ended in 2023.
US protection ended in 2023, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Bristol Myers Squibb. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 3 | 2 | 1 |
| Phase 1 | 4 | 3 | 1 | 0 |
| Phase 2 | 30 | 18 | 6 | 5 |
| Phase 3 | 5 | 2 | 2 | 0 |
| Phase 4 | 15 | 10 | 1 | 2 |
| All trials | 63 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Applicant and Lead sponsor of trials | 2011 to now |